Irem Oner
Ankara, 06200, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 07, 2025
PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: International journal of clinical oncology
Published: January 22, 2025
A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy.
Journal: Medicina (Kaunas, Lithuania)
Published: January 20, 2025
Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors.
Journal: Japanese journal of clinical oncology
Published: January 02, 2025
Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer.
Journal: Future oncology (London, England)
Published: November 26, 2024
Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors.
Journal: Current oncology (Toronto, Ont.)
Published: October 16, 2024
Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy.
Journal: BMC cancer
Published: August 12, 2024
Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume.
Journal: Current oncology (Toronto, Ont.)
Published: July 29, 2024
Effects of BRCA variation on prognosis in patients with nonmetastatic breast cancer.
Journal: Annals of human genetics
Published: May 28, 2024
Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Journal: Clinical breast cancer
Published: March 10, 2024
Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study.
Journal: International journal of clinical oncology
Published: February 12, 2024
Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 10, 2023
Last Updated: 09/26/2026